Possibia

6154291

Last Update Posted: 2025-04-06

Recruiting

All Genders

accepted

18 Years +

255 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

FIH XON7 in Advanced/Metastatic Solid Tumors

This is a two-stage trial consisting of a Part I, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), if any, and Recommended Part 2 Dose (RP2D) of XON7, followed by a Part II component to investigate anti-tumors efficacy in selected solid tumor types and to further evaluate safety and tolerability of XON7 at RP2D.

Eligibility

Relevant conditions:

Advanced Solid Tumor

Metastatic Cancer

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Data sourced from ClinicalTrials.gov